The development of novel drugs: the role of lyophilization
As the pharmaceutical industry focuses on complex, potentially life changing biologics, lyophilization, or freeze-drying, has become essential for the successful…
All articles by
-
-
Optimising outcome measures in cognitive drug trials for schizophrenia
To date, no drugs have been successfully approved for the cognitive symptoms of schizophrenia, despite the impact of these symptoms…
-
How clinical trials can use AI responsibly and effectively
From machine learning (ML) to large language models (LLMs), the applications of AI to clinical trials are multitudinous. Most notably,…
-
Developing high-potent APIs: The necessary steps to follow
The demand for high-potency active pharmaceutical ingredients (HPAPIs) has risen significantly in recent years, driven by the concurrent market growth…
-
Cybersecurity in clinical trials: safeguarding patient data against digital breaches
According to the HIPAA Journal, healthcare data breaches hit an all-time high in 2023, with over 133 million patient records…
-
Gene therapy: How Veristat cut trial database costs by 30%
The gene therapy market is predicted to experience rapid growth over the coming years. But with that growth will come many complexities…
-
Non-small cell lung cancer: the global clinical trials landscape 2024
Lung cancer is the leading cause of cancer deaths globally. Non-small cell lung cancer, which originates from larger cells such…
-
Untapped opportunities: Fulfilling the promise of decentralized clinical trials
The uptake of decentralized clinical trials (DCTs) solutions was greatly accelerated by the COVID-19 pandemic, with lockdowns necessitating that research…
-
Cystic fibrosis: global clinical trials landscape and treatments
Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene, affecting chloride and bicarbonate transport in…
-
How to identify and remove CNS assessment errors to avoid jeopardising a trial
WCG Clinical reports that failure rates for clinical trials involving the central nervous system (CNS) exceed 85% during Phases II…